Stem Cell-Based Interventions for COVID-19: A Systematic Evaluation
Stem Cells
DOI:
https://doi.org/10.22034/JATE.2024.108Keywords:
Mesenchymal stem cells, Stem cell therapy, COVID-19, Clinical TrialsAbstract
Introduction: The emergence of the COVID-19 pandemic has prompted an urgent search for effective therapeutic interventions. Mesenchymal stem cell (MSC) therapy has garnered significant attention due to its potential immunomodulatory and regenerative properties. This systematic review aims to evaluate the safety and efficacy of MSC therapy for COVID-19 treatment and introduce the principal aspects of using MSCs as therapeutic agents.
Methods: A systematic search of major databases including PubMed and Scopus, was conducted to identify relevant studies published up to January 2020 and January 2023. Eligible studies were critically appraised for methodological quality, and data on safety outcomes, including adverse events, and efficacy outcomes, such as clinical improvement and mortality rates, were synthesized. Moreover, we searched the clinical trial registry website and extracted detailed information on registered stem cell therapies for COVID-19 patient treatment.
Results: Preliminary findings demonstrate that MSC therapy holds promise as a potential treatment option for severe COVID-19 patients, indicating favorable safety profiles and encouraging clinical outcomes.
Conclusion: However, preliminary findings confirm the helpful impact of MSC therapy for COVID-19, but further well-designed randomized controlled trials are warranted to establish the optimal dosing regimens, the timing of administration, and the long-term effects of MSC therapy in COVID-19 management.
References
References
Burstein SH, Lin Y, Wu W, Ge Q. ur l P re. Prostaglandins Other Lipid Mediat 2020;95:106408.
Woods JA, Hutchinson NT, Powers SK, Roberts WO, Gomez-Cabrera MC, Radak Z, et al. The COVID-19 pandemic and physical activity. Sport Med Heal Sci 2020;2:55–64. https://doi.org/10.1016/j.smhs.2020.05.006.
Cubero N, Diez-ferrer M, Tebé C. Journal Pre-proof 2020.
Wong ACP, Li X, Lau SKP, Woo PCY. Global epidemiology of bat coronaviruses. Viruses 2019;11:1–17. https://doi.org/10.3390/v11020174.
Nidovirales. Virus Taxon 2012:784–94. https://doi.org/10.1016/b978-0-12-384684-6.00066-5.
Han Q, Guo M, Zheng Y, Zhang Y, De Y, Xu C, et al. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:1–15. https://doi.org/10.3389/fphar.2020.615972.
Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging Dis 2020;11:216–28. https://doi.org/10.14336/AD.2020.0228.
Garcia-ponce EE, Tagg C. Roles ur na l P re of. System 2020:102376.
Kobolak J, Dinnyes A, Memic A, Khademhosseini A, Mobasheri A. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods 2016;99:62–8. https://doi.org/10.1016/j.ymeth.2015.09.016.
Zhao K, Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol 2016;9:1–9. https://doi.org/10.1186/s13045-016-0276-z.
Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 2014;54:1418–37. https://doi.org/10.1111/trf.12421.
Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 2012;35:213–21. https://doi.org/10.1007/s12272-012-0202-z.
Jayaramayya K, Mahalaxmi I, Subramaniam MD, Raj N, Dayem AA, Lim KM, et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep 2020;53:400–12. https://doi.org/10.5483/BMBRep.2020.53.8.121.
Beig G, Sahu SK, Singh V, Tikle S, Sobhana SB, Gargeva P, et al. Jo ur l P of. Sci Total Environ 2019:136126.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6. https://doi.org/10.1371/JOURNAL.PMED.1000100.
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev 2020;29:747–54. https://doi.org/10.1089/scd.2020.0080.
Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 2020;11:361. https://doi.org/10.1186/s13287-020-01875-5.
Patel AN, Vargas V, Revello P, Bull DA. Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue. Cell Transpl 2013;22:513–9. https://doi.org/10.3727/096368912x655064.
Gupta A, El-Amin SF, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord-derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res 2020;15:49. https://doi.org/10.1186/s13018-020-1553-7.
Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021;10:660–73. https://doi.org/10.1002/sctm.20-0472.
Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial 2020;5.
Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 2020;11. https://doi.org/10.1186/S13287-020-01875-5.
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Reports 2020;16. https://doi.org/10.1007/s12015-020-09973-w.
Cui C-H, Uyama T, Miyado K, Terai M, Kyo S, Kiyono T, et al. Menstrual blood-derived cells confer human dystrophin expression in the murine model of Duchenne muscular dystrophy via cell fusion and myogenic transdifferentiation. Mol Biol Cell 2007;18:1586–94.
Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther 2019;10:1. https://doi.org/10.1186/s13287-018-1105-9.
Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. Clin Transl Med 2021;11:e297. https://doi.org/10.1002/ctm2.297.
Lu J, Xie Z-Y, Zhu D-H, Li L-J. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature. World J Clin Cases 2021;9:1705–13. https://doi.org/10.12998/wjcc.v9.i7.1705.
Othmani AE, Rouam S, Abbad A, Erraoui C, Harriba S, Boukind H, et al. Cryopreservation Impacts Cell Functionality of Long Term Expanded Adipose-Derived Stem Cells. J. Stem Cell Res Ther 2019;9:445.
Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata-Martínez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 2020;25:100454.
Study Details | Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | ClinicalTrials.gov 2020. https://clinicaltrials.gov/study/NCT04352803 (accessed April 25, 2024).
Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014;15:4142–57.
Sarvar DP, Shamsasenjan K, Akbarzadehlaleh P. Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy. Adv Pharm Bull 2016;6:293–9. https://doi.org/10.15171/apb.2016.041.
Kouroupis D, Lanzoni G, Linetsky E, Messinger Cayetano S, Wishnek Metalonis S, Leñero C, et al. Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. Eur Rev Med Pharmacol Sci 2021;25:4435–8. https://doi.org/10.26355/eurrev_202106_26156.
Hashemian S-MR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini S-E, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther 2021;12:91. https://doi.org/10.1186/s13287-021-02165-4.
Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 2021;6:58. https://doi.org/10.1038/s41392-021-00488-5.
O. Ercelen N, Pekkoc-Uyanik KC, Alpaydin N, Gulay GR, Simsek M. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. Stem Cell Rev Reports 2021;17:1917–25. https://doi.org/10.1007/S12015-021-10214-X.
Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. Stem Cells Transl Med 2021;10:1279–87. https://doi.org/10.1002/sctm.21-0046.
Guo Z, Chen Y, Luo X, He X, Zhang Y, Wang J. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care 2020;24:1–3.
Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID‐19 pneumonia: A pilot study. Cell Prolif 2020;53:e12947.
Peng H, Gong T, Huang X, Sun X, Luo H, Wang W, et al. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res Ther 2020;11:1–6.
Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore) 2020;99.
Silva KN, Pinheiro P, Gobatto A, Passos R, Paredes B, França L, et al. Intravenous Administration of Umbilical Cord Mesenchymal Stromal Cells in Advanced-stage Critical COVID-19: a Case Report 2020.
Zhu Y, Zhu R, Liu K, Li X, Chen D, Bai D, et al. Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: A case report. Infect Drug Resist 2020;13:3295.
Zengin R, Beyaz O, Koc ES, Akinci IO, Kocagoz S, Sagcan G, et al. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. Stem Cell Investig 2020;7:17. https://doi.org/10.21037/sci-2020-024.
Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, et al. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant 2021;30:9636897211024942. https://doi.org/10.1177/09636897211024942.
Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, et al. Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther 2021;12:410. https://doi.org/10.1186/s13287-021-02483-7.
Zhang Y, Ding J, Ren S, Wang W, Yang Y, Li S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 2020;11:207. https://doi.org/10.1186/s13287-020-01725-4.
Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med 2020;14:664–73.
Chen X, Shan Y, Wen Y, Sun J, Du H. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. J Infect 2020;81:647–79.
Kesari S, Kasper GC, Verkh L, Hammond TC, Matal ML, Hammerling JW, et al. Mesenchymal stem cells in the treatment of severe COVID-19. Transl Med Commun 2021;6:1–4.
Mazzeo A, Santos EJC. Mesenchymal stem cells in the treatment of coronavirus-induced pneumonia (COVID-19). Einstein (Sao Paulo) 2020;18:eCE5802. https://doi.org/10.31744/einstein_journal/2020ce5802.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The Journal of Applied Tissue Engineering
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
